W. L. Gore & Associates announced the first usage of its FDA 510(k) cleared GORE Flow Reversal System for neuroprotection during carotid artery stenting (CAS). It was used in procedure performed by Daniel McCormick, MD and Sheldon Goldberg, MD, Interventional Cardiologists at Hahnemann University Hospital, Philadelphia, Pennsylvania. This new technology minimizes the risk of emboli reaching the brain during critical stages of CAS, thereby expanding treatment options for broad patient populations with carotid artery disease. The first patient was suffering from extreme aortic arch and a string sign lesion in the internal carotid artery. The GORE Flow Reversal System treated lesion successfully under neuroprotection. The patient is doing well after the treatment. The device’s unique technology establishes neuroprotection by reversing blood flow at the treatment site prior to crossing the lesion which is achieved by selectively occluding common carotid and external carotid artery blood flow. The blood from collateral vessels via the Circle of Willis is redirected to the lower pressure venous return by establishing an arterio-venous shunt. During flow reversal Macro and micro emboli are continuously directed away from the brain. Gore is conducting other clinical studies in the area of stroke intervention that include Gore REDUCE Clinical Study to study the GORE HELEX Septal Occluder for patent foramen ovale closure and stroke prevention, and the Gore EMBOLDEN Study to evaluate the GORE Embolic Filter in CAS.